Novo Integrated Sciences Stock Forecast: NVOS Outlook
If you’ve typed “novo integrated sciences stock forecast” into a search bar, you’ve probably already run into the same wall everyone else does: five different sites, five different prices, and not one of them agrees on what happens next. That’s not a glitch. NVOS is a thinly traded over-the-counter healthcare stock, and stocks like this don’t behave like Apple or Microsoft. A quiet Tuesday can move the price 20% on almost no volume.
This piece walks through where Novo Integrated Sciences (NVOS) stands today, why forecasting it is harder than it looks, and what actually tends to move the share price. It’s not a prediction, and anyone promising you a confident price target for a stock like this is selling something.
Who Is Novo Integrated Sciences, Anyway?
Novo Integrated Sciences is a Bellevue, Washington-based healthcare company, not a biotech waiting on an FDA decision, which is a distinction that gets lost in a lot of forecast articles. Through its Canadian and U.S. subsidiaries, the company runs physiotherapy clinics, eldercare and rehabilitation programs, and a medical technology arm built around telehealth and remote patient monitoring. Revenue comes from actual clinical services and product sales, not from a single drug candidate’s trial results.
That matters for how you read a forecast. A biotech’s stock can spike or crater overnight on one FDA letter. NVOS moves more on cash position, dilution, and exchange status than on any single catalyst. For a fuller rundown of the business segments and history, the site’s comprehensive overview of Novo Integrated Sciences is worth a read alongside this one.
Why Every Price You See Looks Different
Here’s the part most forecast pages skip past. Novo used to trade on the Nasdaq Capital Market. In early 2024, the company failed to hold the required $1.00 minimum bid price for 30 straight trading days, missed its compliance window, and was handed a delisting determination. The stock now trades over-the-counter, which comes with thinner liquidity, wider bid-ask spreads, and quotes that can lag depending on which data provider you’re looking at and when they last refreshed.
On top of that, NVOS isn’t new to reverse splits. The company executed 1-for-10 reverse splits in both February 2021 and November 2023, both aimed at meeting exchange price requirements at the time. Older charts and cached articles sometimes still reflect pre-split numbers, which is exactly how you end up with three tabs open showing three different “current” prices. If you want the full mechanics of how these splits worked and what ratios applied, there’s a dedicated breakdown of the NVOS reverse split history that goes deeper than we will here, visit more.
The honest takeaway: don’t trust a static number on any single page, including this one. Pull a live quote from OTC Markets or your brokerage before you make any decision.
NVOS Snapshot
Treat this as a structural summary, not a live feed. Numbers on micro-cap OTC names go stale within hours.
| Detail | Information |
| Ticker | NVOS |
| Company | Novo Integrated Sciences, Inc. |
| Headquarters | Bellevue, Washington |
| Sector | Healthcare services, rehabilitation, medical technology |
| Current exchange | OTC Markets (previously Nasdaq Capital Market) |
| Reverse splits to date | 1-for-10 (Feb 2021), 1-for-10 (Nov 2023) |
| Nasdaq status | Delisting determination issued in 2024 |
| Typical liquidity | Low; thin volume, wide spreads |
| Risk level | High — micro-cap, dilution-prone, off-exchange |
What Actually Moves the NVOS Price
Broad market sentiment barely registers here. A handful of company-specific factors do most of the work.
Cash burn and dilution: Small healthcare companies that aren’t consistently profitable often fund operations through new share issuance, warrants, or convertible notes. Each raise can dilute existing holders, which caps upside even when the underlying clinics or product lines are doing fine. If you’re evaluating NVOS, this matters more than almost anything else on this list.
Subsidiary and partnership news: Novo periodically announces agreements tied to its clinical or technology subsidiaries. These headlines can trigger a sharp, short-lived pop that fades once the news cycle moves on to the next thing. Worth noting, not worth chasing.
Exchange status: Trading on OTC Markets instead of Nasdaq changes who’s even allowed to buy in. Plenty of institutional funds and some retail brokerages restrict OTC trading outright, which keeps demand structurally lower than it would be on a major exchange.
Retail chatter: With a low share price and periods of thin float, NVOS attracts the kind of retail trading activity that can swing on message-board sentiment as much as on fundamentals. It’s worth checking that pulse alongside the numbers — the NVOS Stocktwits sentiment tracker gives a decent read on what retail traders are actually saying day to day, and the site’s earlier NVOS StockTwits recap covers a different slice of the same conversation.
Bull Case vs. Bear Case
None of this is a prediction. It’s the realistic range of outcomes for a micro-cap healthcare stock trading off-exchange with a reverse-split history.
| Scenario | What would need to happen | Main risk |
| Bullish | Steady revenue growth across the clinical business, progress back toward exchange compliance, slower dilution | Execution risk; margins in small-cap healthcare services are thin to begin with |
| Bearish | Continued cash burn, more dilutive raises, OTC liquidity thinning further | Existing shareholders keep getting diluted with each new raise |
| Base case | Range-bound trading driven by news spikes rather than a sustained trend | Forecasting accuracy is genuinely low for a stock trading at this volume |
How to Check the Real Number Yourself
Skip the forecast headlines and go straight to the source before you act on anything.
- Pull a live quote from OTC Markets or your broker’s feed rather than a cached search result.
- Confirm whether the price you’re looking at is split-adjusted. NVOS has a reverse-split history that trips up older articles constantly.
- Read the most recent SEC filings for cash position and outstanding share count. These two numbers tell you more about where the stock is headed than a day’s price action ever will.
- Cross-check community sentiment against the fundamentals rather than treating either one alone as the full picture. This volatility analysis of NVOS walks through how the two interact.
Is NVOS a Good Investment?
Nobody can answer that for you, and any article that tries is overreaching. What’s fair to say: NVOS carries the risk profile common to OTC micro-cap healthcare names — thin volume, a documented history of shareholder dilution, and an exchange status that limits who can even hold the stock. None of that rules out the underlying business improving over time. It does mean a forecast for this stock is inherently less reliable than one for a company with years of analyst coverage behind it.
Anyone considering a position should treat every scenario in this article, and any specific price target found elsewhere, as a rough sketch rather than a plan to bet on. This isn’t financial or legal advice, and a stock this volatile can move fast in either direction on very little notice. For a broader look at how the company frames its own outlook, the site’s full NVOS stock forecast breakdown is a useful companion read to this piece. You can also learn more about how this site approaches NVOS coverage on the About Us page, or reach out through Contact Us with specific questions.
FAQs
Is Novo Integrated Sciences still listed on Nasdaq?
No. The company received a delisting determination in 2024 after failing to hold Nasdaq’s minimum bid price requirement, and shares now trade over-the-counter.
Why do different sites show different NVOS prices?
Because it’s thinly traded, quotes update at different speeds across data providers, and older articles sometimes reflect pre-split numbers. Always confirm against a live OTC Markets or broker quote before trusting any figure.
Has NVOS done a reverse stock split before?
Yes, twice — a 1-for-10 split in February 2021 and another 1-for-10 split in November 2023, both intended to meet exchange price requirements.
What does Novo Integrated Sciences actually do?
It runs a multidisciplinary primary healthcare business, including physiotherapy, rehabilitation, and eldercare services, plus a medical technology division covering telehealth and remote patient monitoring.
Can I trust a specific price target for NVOS?
Treat any specific number with caution. Analyst coverage on micro-cap OTC stocks is limited, and price action tends to follow news catalysts and liquidity swings rather than steady, fundamentals-driven trends.
Where should I check the current NVOS price before investing?
Go directly to OTC Markets or your brokerage’s live feed. Search snippets and cached articles, including this one, can lag what’s actually trading.
Conclusion
A novo integrated sciences stock forecast is only as reliable as the data feeding it, and for this particular stock, that data shifts fast. NVOS moved off Nasdaq to OTC trading in 2024, carries a reverse-split history that confuses a lot of secondhand coverage, and trades with the kind of volatility that turns a confident price target into a coin flip dressed up as analysis.
If you’re researching this stock, spend more time on cash position, dilution trends, and exchange status than on any single forecast number floating around online, including this article. Then confirm live pricing before you make a call either way.
